Compounded vs. brand-name GLP-1s: what the science actually says

What's this video probably claiming?

Based on the caption and hashtag mix, this creator is likely positioning compounded GLP-1s as a cost-accessible alternative to name-brand semaglutide and tirzepatide, while flagging some safety considerations. The framing, "what you NEED to know to stay safe," is a classic hedge that lets creators appear responsible while still validating the compounded route. Given the hashtags include both "semiglutide" (misspelled) and "tirzepatide," this video is probably covering both drug classes in one breath, which is already a problem. Semaglutide and tirzepatide have completely different mechanisms, approval histories, and compounding legal statuses. Lumping them together flattens distinctions that actually matter for patient safety. The video likely presents a side-by-side comparison suggesting compounded versions are roughly equivalent to name-brand, with the main tradeoff being price. That framing needs serious scrutiny.

What does the science actually show?

The evidence base for brand-name semaglutide is genuinely strong. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight reduction over 68 weeks with 2.4mg weekly subcutaneous semaglutide in adults with obesity. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg achieving up to 20.9% weight reduction over 72 weeks. These numbers come from tightly controlled trials using pharmaceutical-grade, FDA-approved formulations with verified bioavailability and sterility standards. Compounded semaglutide, by contrast, has no equivalent clinical trial data. The FDA does not evaluate compounded drugs for efficacy or safety before they reach patients. Some compounded versions have also included additives like vitamin B12 or NAD+ with zero clinical justification for the combination, and at least one compounded semaglutide salt (semaglutide sodium) is chemically distinct from the approved base form.

Where does the social media noise diverge from clinical reality?

The biggest distortion happening across GLP-1 content right now is the implication that compounded equals equivalent, just cheaper. It does not, and regulators have said so explicitly. The FDA issued a statement in 2024 warning that compounded semaglutide products are not the same as Ozempic or Wegovy, and that they have received reports of adverse events, including dosing errors, from patients using compounded versions. Some of those errors stemmed from concentration differences in compounded vials compared to pre-filled pens. Beyond safety signals, there is a legal dimension most creators ignore entirely. FDA placed semaglutide on its shortage list, which legally permitted compounding under 503A and 503B exemptions. Once FDA declared the shortage resolved in early 2025, the legal basis for most compounded semaglutide evaporated. Tirzepatide's shortage status has followed a similarly complicated path. Creators talking about "compounded GLP-1s" in 2025 without addressing these regulatory shifts are missing half the story.

What should you actually know?

If you are considering a compounded GLP-1 for weight management, the most important thing to understand is that you are operating outside the clinical trial evidence base. That is not automatically disqualifying, but it requires more scrutiny, not less. Ask your prescriber which pharmacy is compounding it, whether it is a 503B outsourcing facility (which has higher FDA oversight than a standard 503A compounding pharmacy), and whether the formulation uses semaglutide free base or a salt form. The American Society of Health-System Pharmacists and the Endocrine Society have both raised concerns about quality variability across compounders. Cost savings are real, often significant, but they come with genuine tradeoffs in quality assurance and legal certainty. Anyone presenting this as a simple cost-benefit calculation is leaving out regulatory and pharmacological complexity that patients deserve to understand before injecting anything.